Market Overview

UPDATE: Aegis Capital Raises PT to $3.50 on Neuralstem on Clinical Progress

Related CUR
Actinium Set To Follow In Opko's Foosteps Amid Near Term Catalysts
Neuralstem Reports First Patient Treated In China Stem Cell Trial to Treat Stroke Motor Deficits

Aegis Capital reiterated its Buy rating on Neuralstem (NYSE: CUR) and increased its price target from $3 to $3.50.

Aegis Capital commented, "We have been encouraged by Neuralstem's recent progress in the clinical development of both its stem cell platform, designated NSI-566, and its small molecule program, designated NSI-189. … From our perspective, the bear thesis on Neuralstem seems to have little merit at this juncture. We note that, while there is relatively little efficacy data as of yet, what has been revealed has largely been positive in nature. Further, the recent publication of research focusing on the firm's stem cell technology in the journal Cell is cause for confidence, in our view, as Cell is the highest impact factor life science journal in the world."

Neuralstem closed at $1.16 on Friday.

Latest Ratings for CUR

DateFirmActionFromTo
Jan 2013Aegis CapitalMaintainsBuy
Dec 2012Aegis CapitalMaintainsBuy
Jul 2012Aegis CapitalInitiates Coverage onBuy

View More Analyst Ratings for CUR
View the Latest Analyst Ratings

Posted-In: Aegis CapitalPrice Target Intraday Update Analyst Ratings

 

Related Articles (CUR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional